explore -WSS

explore

author：Wikipedia 2025-09-27 09:57:47 - browse：245

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： STAT Virtual Event: ASCO Recap, Live!

leisure time

WSS

Cigna wins case to block Amy Bricker's move to CVS

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Eye stem cell transplant could help restore vision in injured people

5 takeaways from STAT's examination of Zynex Medical

Eye stem cell transplant could help restore vision in injured people

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

leisure time

explore

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

'Essentially witchcraft:' A former naturopath takes on the field

As demand for Covid shots wanes, Moderna seeks its next success

Cigna wins case to block Amy Bricker's move to CVS

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medical device trials still don't enroll enough women, study finds

Virginia high school admissions case could be legal follow

New definition of a human embryo proposed amid rapid advances

Medicare proposal to cover medical devices draws a mixed reaction

New report analyzes digital physical therapy solutions' effectiveness

knowledge

Teladoc has a new CEO, but challenges remain the same

Cheap, fast test for Zika and dengue could cost just $1

ProMED sees offers of support, but its future remains unclear

ALS patient reclaims some autonomy thanks to wearable 'robot'

How faith leaders like me can help address America's obesity epidemic

Hilary may become 1st tropical storm to make landfall in California in 84 years

Wikipedia

leisure time

hotspot

focus